Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl clinical trials

Explore recruiting relapsed or refractory diffuse large b cell lymphoma dlbcl clinical trials.

Recruiting relapsed or refractory diffuse large b cell lymphoma dlbcl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Hungary, Italy, Belgium, France, Netherlands, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Austria, Poland, Italy, Czechia, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

C5691003_A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) ECHELON-3

Spain, Belgium, Italy, Denmark, Czechia, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl trials by city

Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Toronto Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Vancouver Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Montreal Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Calgary Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Edmonton Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Ottawa Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Winnipeg Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Quebec City Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Hamilton Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Kitchener Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in London Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Halifax Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in New York Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Los Angeles Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Chicago Relapsed Or Refractory Diffuse Large B Cell Lymphoma Dlbcl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease